Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 28, 2015; 7(18): 2155-2161
Published online Aug 28, 2015. doi: 10.4254/wjh.v7.i18.2155
Published online Aug 28, 2015. doi: 10.4254/wjh.v7.i18.2155
Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma
Fauzia Z Khan, Ryan B Perumpail, Aijaz Ahmed, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States
Robert J Wong, Division of Gastroenterology and Hepatology, Alameda Health System - Highland Hospital Campus, Oakland, CA 94602, United States
Author contributions: Khan FZ, Perumpail RB, Wong RJ and Ahmed A developed an outline for the review article; Khan FZ, Perumpail RB, Wong RJ and Ahmed A performed research; Khan FZ, Perumpail RB, Wong RJ and Ahmed A performed a medline search to review the published data on this topic; Khan FZ and Perumpail RB prepared the initial and final draft based on input from senior authors; Wong RJ and Ahmed A reviewed each section of the manuscript and provided critical mentorship to complete this review article.
Conflict-of-interest statement: We declare that we have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Aijaz Ahmed, MD, Associate Professor of Medicine, Medical Director Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite 210, Palo Alto, Stanford, CA 94305, United States. aijazahmed@stanford.edu
Telephone: +1-650-4986091 Fax: +1-650-4985692
Received: April 24, 2015
Peer-review started: April 24, 2015
First decision: July 17, 2015
Revised: July 22, 2015
Accepted: August 16, 2015
Article in press: August 17, 2015
Published online: August 28, 2015
Processing time: 127 Days and 16.1 Hours
Peer-review started: April 24, 2015
First decision: July 17, 2015
Revised: July 22, 2015
Accepted: August 16, 2015
Article in press: August 17, 2015
Published online: August 28, 2015
Processing time: 127 Days and 16.1 Hours
Core Tip
Core tip: The worldwide rise in overweight and obesity has been associated with increasing rates of nonalcoholic fatty liver disease (NAFLD), which is now the most common etiology of chronic liver disease. The more aggressive form of NAFLD, nonalcoholic steatohepatitis (NASH), promotes the development of hepatocellular carcinoma (HCC). As NASH-related cirrhosis has emerged as the most rapidly increasing indication for HCC-related liver transplantation in the United States, new strategies for HCC surveillance and targeted therapies in this patient population are warranted.